Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been given a consensus rating of "Buy" by the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $63.67.

A number of research firms have recently weighed in on TARS. HC Wainwright restated a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Guggenheim reissued a "buy" rating and set a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Oppenheimer upped their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Jefferies Financial Group lifted their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Finally, Barclays lowered their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th.

Tarsus Pharmaceuticals Stock Up 0.9 %

Shares of Tarsus Pharmaceuticals stock traded up $0.44 during trading on Friday, reaching $47.59. 317,090 shares of the company traded hands, compared to its average volume of 637,197. The firm has a market capitalization of $1.83 billion, a PE ratio of -12.51 and a beta of 1.05. The company has a 50 day moving average price of $49.60 and a 200-day moving average price of $44.29. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals has a 1-year low of $20.08 and a 1-year high of $57.28.

Remove Ads

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million for the quarter, compared to analysts' expectations of $58.80 million. As a group, equities research analysts expect that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Toronto Dominion Bank purchased a new position in Tarsus Pharmaceuticals during the fourth quarter worth about $105,714,000. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter valued at about $44,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $3,278,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Tarsus Pharmaceuticals by 18.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 69,826 shares of the company's stock worth $3,866,000 after purchasing an additional 10,991 shares during the last quarter. Finally, Woodline Partners LP raised its stake in Tarsus Pharmaceuticals by 52.3% in the fourth quarter. Woodline Partners LP now owns 108,986 shares of the company's stock valued at $6,035,000 after purchasing an additional 37,417 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.